Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs

Metabolic side effects such as weight gain and disturbed lipid metabolism are often observed in the treatment of atypical antipsychotic drugs (AAPDs), which contribute to an excessive prevalence of metabolic syndrome among schizophrenic patients. Great individual differences are observed but the underlying mechanisms are still uncertain. Research on pharmacogenomics indicates that gene polymorphisms involved in the pathways controlling food intake and lipid metabolism may play a significant role. In this review, relevant genes (HTR2C, DRD2, LEP, NPY, MC4R, BDNF, MC4R, CNR1, INSIG2, ADRA2A) and genetic polymorphisms related to metabolic side effects of AAPDs especially dyslipidemia were summarized. Apart from clinical studies, in vitro and in vivo evidence is also analyzed to support related theories. The association of central and peripheral mechanisms is emphasized, enabling the possibility of using peripheral gene expression to predict the central status. Novel methodological development of pharmacogenomics is in urgent need, so as to provide references for individualized medication and further to shed some light on the mechanisms underlying AAPD-induced lipid disturbances.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

Patients with a diagnosis of schizophrenia are at an increased risk for developing metabolic syndrome, which is associated with greater cardiovascular morbidity and mortality. Treatment with some commonly used...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Research article Source Type: research
IntroductionThe co-existence of schizophrenia and metabolic syndrome is a widely described phenomenon that contributes to the worse functioning of patients in everyday life. A relatively new area of research is the relationship between metabolic syndrome (MS) and cognitive function in patients with schizophrenia. The aim of the study was to verify the relationship between the presence of metabolic syndrome and cognitive function of patients with schizophrenia and to assess the possibility of changing cognitive function by introducing appropriate dietary intervention.Materials and MethodsThe study involved 87 individuals di...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Authors: Bueno-Antequera J, Munguía-Izquierdo D Abstract Schizophrenia is a psychiatric disorder characterized by distortions of thinking and perception, with no strictly pathognomonic symptoms that can be divided into positive, negative, and cognitive symptom domains. People with schizophrenia have, between others, a reduced life expectancy and cardiorespiratory and muscular fitness and increased risk of cardiovascular disease, metabolic syndrome, obesity, hypertension, and hyperlipidemia compared to the general population. Furthermore, the economic burden of mental disorders including schizophrenia is evid...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Altered Peripheral Blood Compounds in Drug-Naïve First-Episode Patients With Either Schizophrenia or Major Depressive Disorder, A Meta-Analysis. Brain Behav Immun. 2020 Apr 21;: Authors: Çakici N, Sutterland AL, W J H Penninx B, Dalm VA, de Haan L, van Beveren NJM Abstract IMPORTANCE: Schizophrenia and major depressive disorder (MDD) are associated with increased risks of immunologic disease and metabolic syndrome. It is unclear to what extent growth, immune or glucose dysregulations are similarly present in these disorders without the influence of treatment or chronicity. OBJECTIVE: ...
Source: Brain, Behavior, and Immunity - Category: Neurology Authors: Tags: Brain Behav Immun Source Type: research
Publication date: Available online 15 April 2020Source: Brain, Behavior, and ImmunityAuthor(s): Wei Tang, Yewei Wang, Feikang Xu, Weixing Fan, Yaoyao Zhang, Kaili Fan, Weiping Wang, Yi Zhang, Chen Zhang
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Abstract Our previous study showed that metabolic abnormalities reduced the levels of brain-derived neurotrophic factor (BDNF) and deteriorated cognitive performance in patients with schizophrenia. Inflammation may play a key role in this process. Omega-3 fatty acids have been documented to ameliorate inflammation. Therefore, we hypothesized that omega-3 fatty acids may be of value in enhancing BDNF levels and improving cognitive function in patients with schizophrenia with metabolic syndrome (MetS). We recruited 80 patients with both schizophrenia and MetS who received long-term olanzapine monotherapy. The enzyme...
Source: Brain, Behavior, and Immunity - Category: Neurology Authors: Tags: Brain Behav Immun Source Type: research
Conclusions: An interdisciplinary approach is required between neurosciences and cardiology not only at the research level, but also in the clinical practice. Cardiac co-morbidity in subjects with schizophrenia may critically affect the survival rates of these patients. Moreover, the nature of the cardiac co-morbidity may guide the clinician in better understanding and differentiating functional psychoses from organic ones. The multifactorial approach can identify cardiovascular risk factors based on clinical, biological and neuroimaging markers. PMID: 32239085 [PubMed - in process]
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Authors: Zhang Y, Wang Q, Reynolds GP, Yue W, Deng W, Yan H, Tan L, Wang C, Yang G, Lu T, Wang L, Zhang F, Yang J, Li K, Lv L, Tan Q, Li Y, Yu H, Zhang H, Ma X, Yang F, Li L, Chen Q, Wei W, Zhao L, Wang H, Li X, Guo W, Hu X, Tian Y, Ren H, Ma X, Coid J, Zhang D, Li T, Chinese Antipsychotics Pharmacogenomics Consortium Abstract OBJECTIVE: To compare longitudinal metabolic effects of 7 antipsychotics, including body mass index (BMI), waist circumference (WC), blood pressure (BP), glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C); to investigate ...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Aripiprazole is an atypical antipsychotic that is usually well tolerated. It is FDA approved for treatment for schizophrenia and mania in Bipolar Disorder. Off label use includes augmentation protocols for depression and anxiety disorders as well as aggression in the pediatric population. Properties include 5-HT1A partial agonism and 5HT1-A antagonism along with D2 and D3 agonism. Abilify is often preferred due to reduced risk of metabolic syndrome, extrapyramidal symptoms and minimal sedative profile.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Poster Number: EI-51 Source Type: research
More News: Drugs & Pharmacology | Genetics | Metabolic Syndrome | Schizophrenia | Study